Lichen Sclerosus et Atrophicus Induced by Carbamazepine: A Case Report. (July 2013)

• Record Type: Journal Article
• Authors: Pranteda, G.; Muscianese, M.; Grimaldi, M.; Fidanza, L.; Pranteda, G.; Narcisi, A.; Nisticò, S.; Bottoni, U.
• Is Part Of: International journal of immunopathology and pharmacology. Volume 26:Number 3(2013)
• Page Start: 791
• Page End: 794
• Publication Date: 2013-07
• Subjects: Lichen sclerosus -- drug induced reaction -- carbamazepine -- treatment of chronic skin disorders; Immunopathology -- Periodicals; Pharmacology -- Periodicals; Inflammation -- Periodicals; 615.1
• DOI: 10.1177/039463201302600326
• Languages: English
• ISSNs: 0394-6320

Abstract

We report a case of Lichen Sclerosus in a 73-year-old man who had been treated for epilepsy with carbamazepine. Lichen sclerosus et atrophicus (LSA), also called lichen sclerosus (LS), is a chronic inflammatory cutaneous condition characterized by white plaques with epidermal atrophy and scarring. To date no cases of LSA has been linked to carbamazepine, although in a few cases lichenoid eruptions but without sclero-atrophy have been described after exposure to this drug. Therefore, to our knowledge, this is the first report of a Lichen sclerosus et atrophicus induced by carbamazepine